In this GI oncology update, Dr. Annalice Gandini highlights some of the most important advances and publications in gastrointestinal oncology released during April.
The discussion begins with promising pancreatic cancer data from a Revolution Medicines press release, where daraxonrasib, a pan-RAS inhibitor, demonstrated encouraging survival outcomes in pre-treated metastatic pancreatic cancer.
The video also explores a retrospective multicenter study from the French AGEO group in small bowel adenocarcinoma, showing improved progression-free and overall survival with the addition of anti-angiogenic therapy to chemotherapy.
Pancreatic Cancer, Revolution Medicines Press Release, Daraxonrasib
Small Bowel Adenocarcinoma, AGEO Retrospective Multicenter Study
Colorectal Cancer, ORIGAMI-1 Trial, Amivantamab
Colorectal Cancer, EMOTEP Trial, Perioperative Pembrolizumab
ESMO Guidelines Update for Metastatic Colorectal Cancer